A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...
SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...
The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...
Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...
The addition of PD-1 inhibitors to first-line treatment with transarterial chemoembolization (TACE) plus lenvatinib for hepatocellular carcinoma (HCC). “PD-1 inhibitors have been recognized as an ...
The relationship of preoperative frailty with short- and long-term surgical outcomes among octogenarians with hepatocellular carcinoma: A multicenter comprehensive analysis. This is an ASCO Meeting ...
Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer.
Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally. Often diagnosed at advanced stages, the therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results